Nokomis Ramos-Gonzalez

Nokomis Ramos-Gonzalez

Auto-generated profile, based on publicly available information

Nokomis Ramos-Gonzalez

Center for Clinical Pharmacology, Department of Anesthesiology, Washington University School of Medicine, Saint Louis, MO, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2023 in Pharmacological Research
Verified
Journal Article
Open access
NRNokomis Ramos-Gonzalez
Nokomis Ramos-Gonzalez
BPBarnali Paul
Barnali Paul
SMSusruta Majumdar
Susruta Majumdar
Drugs acting at the opioid receptor family are clinically used to treat chronic and acute pain, though they represent the second line of treatment behind GABA analogs, antidepressants and SSRI's. Within the opioid family mu and kappa opioid receptor are commonly targeted. However, activation of the mu opioid receptor has side effects of constipation, tolerance, dependence, euphoria, and respiratory depression; activation of the kappa opioid receptor leads to dysphoria and sedation. The side effects of mu opioid receptor activation have led to mu receptor drugs being widely abused with great overdose risk. For these reasons, newer safer opioid analgesics are in high demand. For many years a focus within the opioid field was finding drugs that activated the G protein pathway at mu opioid receptor, without activating the β-arrestin pathway, known as biased agonism. Recent advances have shown that this may not be the way forward to develop safer analgesics at mu opioid receptor, though there is still some promise at the kappa opioid receptor. Here we discuss recent novel approaches to develop safer opioid drugs including efficacy vs bias and fine-tuning receptor activation by targeting sub-pockets in the orthosteric site, we explore recent works on the structural basis of bias, and we put forward the suggestion that Gα subtype selectivity may be an exciting new area of interest.

5 March 2025 in Nature
Verified
Journal Article
Closed access
PDF file
VRVipin Ashok Rangari
Vipin Ashok Rangari
EOEvan S. O’bRien
Evan S. O’bRien
APAlexander S. Powers
Alexander S. Powers
RSRichard A. Slivicki
Richard A. Slivicki
ZBZachariah Bertels
Zachariah Bertels
SMSusruta Majumdar
Susruta Majumdar

7 January 2025 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
ATAaliyah S. Tyson
Aaliyah S. Tyson
SKSaif Khan
Saif Khan
ZMZenia Motiwala
Zenia Motiwala
GHGye Won Han
Gye Won Han
ZZZixin Zhang
Zixin Zhang
Cornelius GatiCornelius Gati
Cornelius Gati
Opioid receptors, a subfamily of G protein-coupled receptors (GPCRs), are key therapeutic targets. In the canonical GPCR activation model, agonist binding is required for receptor–G protein complex formation, while antagonists prevent G protein coupling. However, many GPCRs exhibit basal activity, allowing G protein association without an agonist. The pharmacological impact of agonist-free receptor–G protein complexes is poorly understood. Here we present biochemical evidence that certain κ-opioid receptor (KOR) inverse agonists can act via KOR–Gi protein complexes. To investigate this phenomenon, we determined cryo-EM structures of KOR–Gi protein complexes with three inverse agonists: JDTic, norBNI and GB18, corresponding to structures of inverse agonist-bound GPCR–G protein complexes. Remarkably, the orthosteric binding pocket resembles the G protein-free ‘inactive’ receptor conformation, while the receptor remains coupled to the G protein. In summary, our work challenges the canonical model of receptor antagonism and offers crucial insights into GPCR pharmacology.

17 July 2024 in ACS Central Science
Verified
Journal Article
Open access
RORohini S. Ople
Rohini S. Ople
NRNokomis Ramos-Gonzalez
Nokomis Ramos-Gonzalez
QLQiongyu Li
Qiongyu Li
BSBriana L. Sobecks
Briana L. Sobecks
DADeniz Aydin
Deniz Aydin
SMSusruta Majumdar
Susruta Majumdar
The mu opioid receptor (μOR) is a target for clinically used analgesics. However, adverse effects, such as respiratory depression and physical dependence, necessitate the development of alternative treatments. Recently we reported a novel strategy to design functionally selective opioids by targeting the sodium binding allosteric site in μOR with a supraspinally active analgesic named C6guano. Presently, to improve systemic activity of this ligand, we used structure-based design, identifying a new ligand named RO76 where the flexible alkyl linker and polar guanidine guano group is swapped with a benzyl alcohol, and the sodium site is targeted indirectly through waters. A cryoEM structure of RO76 bound to the μOR-Gi complex confirmed that RO76 interacts with the sodium site residues through a water molecule, unlike C6guano which engages the sodium site directly. Signaling assays coupled with APEX based proximity labeling show binding in the sodium pocket modulates receptor efficacy and trafficking. In mice, RO76 was systemically active in tail withdrawal assays and showed reduced liabilities compared to those of morphine. In summary, we show that targeting water molecules in the sodium binding pocket may be an avenue to modulate signaling properties of opioids, and which may potentially be extended to other G-protein coupled receptors where this site is conserved.

22 June 2026 in Nature Structural & Molecular Biology
Verified
Journal Article
Open access
QJQianru Jiang
Qianru Jiang
JHJianming Han
Jianming Han
EFEve J. Fine
Eve J. Fine
NRNokomis Ramos-Gonzalez
Nokomis Ramos-Gonzalez
VRVipin Ashok Rangari
Vipin Ashok Rangari
TCTao Che/Washington Che
Tao Che/Washington Che
Ketamine offers rapid relief for treatment-resistant depression and severe pain in the clinic, providing immediate benefits that traditional medications often fail to deliver. While its antagonistic action at the N-methyl-D-aspartate receptor (NMDAR) is a key mechanism, ketamine's dual nature as both a promising treatment and a drug with abuse potential suggests its therapeutic effects extend beyond NMDAR inhibition. Here we provide structural evidence of human opioid receptors bound to ketamine and its parent analog phencyclidine (PCP), supporting that both ligands can directly bind and activate opioid receptors. The structures, together with site-directed mutagenesis and structure-activity relationship studies, identify key motifs involved in ketamine and PCP recognition and efficacy modulation. Furthermore, we determine the structure of the ligand-free state of human κ opioid receptor, revealing molecular details before ligand engagement. Compared to PCP, ketamine displays more notable binding dynamics in the orthosteric site that may contribute to its unique pharmacology at opioid receptors. Our findings highlight the importance of including opioid receptors to fully understand ketamine's versatility in clinical settings.

26 June 2025 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
BVBalazs R. Varga
Balazs R. Varga
RURajendra Uprety
Rajendra Uprety
BPBarnali Paul
Barnali Paul
AKAlexis Knoll
Alexis Knoll
NRNokomis Ramos-Gonzalez
Nokomis Ramos-Gonzalez
SMSusruta Majumdar
Susruta Majumdar